Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily can
prevent worsening of walking ability in people PPMS. The number of participants in this study
will be 35. A maximum of 42 people with PPMS will be included. The trial is funded through a
private donation to the Hotchkiss Brain Institute MS Translational Clinical Trials Research
Program and the University of Calgary. There is no sponsorship from the pharmaceutical
industry.